Bioatla Inc (BCAB) Stock Price, Quote & News

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcino...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 0708

Fax: 858 558 0709

Website: www.bioatla.com

Address:

11085 Torreyana Road, San Diego, United States

LabPsycho Sep. 11 at 7:21 PM

$BCAB I posted this a year ago, and something similar 2 yr ago... @dudereally

0 · Reply

whateverhappenedthere Sep. 11 at 4:42 PM

$BCAB impressive volume

1 · Reply

Moonlightcat Sep. 8 at 1:52 PM

$BCAB

1 · Reply

PennySearch Sep. 3 at 1:38 PM

📊 Today's Highest Relative Volume $DLTH — 17.44x RVOL Move: +16% Volume: 1.9M (110.1K average) Market Cap: $158.3M $TLYS — 11.62x RVOL Move: +55% Volume: 3.2M (273.8K average) Market Cap: $177.6M $BCAB — 9.39x RVOL Move: +0% Volume: 1.0M (109.9K average) Market Cap: $2.9M High relative volume highlights where market attention is concentrated. Which one are you watching? 👀 Not financial advice.

0 · Reply

PennySearch Sep. 2 at 2:38 PM

⏱️ One-Hour Volume Alert Update $LHAI near $1.15 • 27.92x RVOL Day Range: $1.11 - $1.28 $DH near $1.10 • 13.33x RVOL Day Range: $1.02 - $1.22 $BCAB near $1.74 • 9.61x RVOL Day Range: $1.58 - $2.06 Unusual volume does not guarantee direction—it highlights attention. Not financial advice.

0 · Reply

Moonlightcat Sep. 2 at 10:18 AM

$BCAB the value of this fraud. All assets are being moved to Chinese scam company Himalaya. Still time to sell before the halt.

0 · Reply

biovaluable Sep. 2 at 2:39 AM

$BCAB jay must go jail

0 · Reply

LineOfControl Sep. 1 at 11:10 PM

$BCAB the Board of BioAtla literally did nothing while the company burned to the ground. Nasty work

2 · Reply

lecorb Sep. 1 at 8:52 PM

$ALMS $PMI $BCAB $VWAV BIG CRABS DAY!

0 · Reply

biovaluable Sep. 1 at 10:23 AM

$BCAB trash jay

0 · Reply

Context Therapeutics enters license agreement amendment with BioAtla

CNTX

2026-04-02T23:50:53.000Z - 5 months ago

BioAtla trading halted, news pending

2026-03-31T20:45:40.000Z - 5 months ago

BioAtla announces 50-for-1 share consolidation

Mar 31, 2026, 4:06 PM EDT - 5 months ago

BioAtla Announces Share Consolidation

Mar 31, 2026, 4:05 PM EDT - 5 months ago

BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 2, 2026, 7:30 AM EST - 6 months ago

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

Dec 31, 2025, 7:00 AM EST - 8 months ago

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

Nov 21, 2025, 12:25 AM EST - 9 months ago

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

Nov 13, 2025, 4:05 PM EST - 10 months ago

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

$BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas$

Nov 7, 2025, 9:00 AM EST - 10 months ago

BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

Nov 5, 2025, 8:00 AM EST - 10 months ago

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

Oct 23, 2025, 8:00 AM EDT - 10 months ago

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

$BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025$

Oct 20, 2025, 8:00 AM EDT - 10 months ago

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Oct 3, 2025, 9:00 AM EDT - 11 months ago

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

Sep 8, 2025, 8:00 AM EDT - 1 year ago

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

Aug 7, 2025, 4:05 PM EDT - 1 year ago

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 4, 2025, 8:00 AM EDT - 1 year ago

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 1 year ago

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

$BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress$

Jul 3, 2025, 8:00 AM EDT - 1 year ago

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Jun 2, 2025, 8:00 AM EDT - 1 year ago

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

May 6, 2025, 4:05 PM EDT - 1 year ago

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Apr 30, 2025, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 1 year ago

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 23, 2025, 10:05 AM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 27, 2025, 5:05 PM EDT - 1 year ago

BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 4:05 PM EDT - 1 year ago

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Mar 20, 2025, 8:00 AM EDT - 1 year ago

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Mar 19, 2025, 8:00 AM EDT - 1 year ago

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

Mar 4, 2025, 7:34 AM EST - 1 year ago

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Dec 20, 2024, 9:00 AM EST - 1 year ago

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Dec 16, 2024, 8:00 AM EST - 1 year ago

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 10, 2024, 8:00 AM EST - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 1, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Sep 23, 2024, 7:30 AM EDT - 1 year ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Jul 25, 2024, 5:39 PM EDT - 2 years ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

May 29, 2024, 8:00 AM EDT - 2 years ago

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 2 years ago

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 4:05 PM EDT - 2 years ago

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 8, 2024, 8:00 AM EDT - 2 years ago

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 2 years ago

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

Apr 24, 2024, 4:35 PM EDT - 2 years ago

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 26, 2024, 4:01 PM EDT - 2 years ago

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Mar 19, 2024, 8:00 AM EDT - 2 years ago

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

Mar 7, 2024, 8:00 AM EST - 2 years ago

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Dec 20, 2023, 8:00 AM EST - 2 years ago

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 13, 2023, 8:00 AM EST - 2 years ago

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Dec 6, 2023, 8:00 AM EST - 2 years ago

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

Dec 5, 2023, 8:00 AM EST - 2 years ago

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Nov 30, 2023, 8:00 AM EST - 2 years ago

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

Nov 28, 2023, 8:00 AM EST - 2 years ago

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

LabPsycho Sep. 11 at 7:21 PM

$BCAB I posted this a year ago, and something similar 2 yr ago... @dudereally

0 · Reply

whateverhappenedthere Sep. 11 at 4:42 PM

$BCAB impressive volume

1 · Reply

Moonlightcat Sep. 8 at 1:52 PM

$BCAB

1 · Reply

PennySearch Sep. 3 at 1:38 PM

0 · Reply

PennySearch Sep. 2 at 2:38 PM

0 · Reply

Moonlightcat Sep. 2 at 10:18 AM

$BCAB the value of this fraud. All assets are being moved to Chinese scam company Himalaya. Still time to sell before the halt.

0 · Reply

biovaluable Sep. 2 at 2:39 AM

$BCAB jay must go jail

0 · Reply

LineOfControl Sep. 1 at 11:10 PM

$BCAB the Board of BioAtla literally did nothing while the company burned to the ground. Nasty work

2 · Reply

lecorb Sep. 1 at 8:52 PM

$ALMS $PMI $BCAB $VWAV BIG CRABS DAY!

0 · Reply

biovaluable Sep. 1 at 10:23 AM

$BCAB trash jay

0 · Reply

Moonlightcat Sep. 1 at 7:29 AM

$BCAB

0 · Reply

OldCarGuy Aug. 31 at 9:59 PM

$BCAB

1 · Reply

TwongStocks Aug. 31 at 12:41 PM

$BCAB Now trading OTC, on the OTCID Basic Market. https://www.otcmarkets.com/stock/bcab/overview

0 · Reply

biovaluable Aug. 31 at 11:34 AM

$CNTX only donated a huge amount of cash to $BCAB , which was delisted due to failed technology. It was a pipeline that could be obtained for free if you waited just a little longer. Of course, the chance of failure is high, though.

0 · Reply

saad545 Aug. 31 at 9:27 AM

$BCAB $CNTX don’t worry , you will be burned🔥🔥

0 · Reply

biovaluable Aug. 31 at 5:53 AM

$BCAB https://www.linkedin.com/in/jay-short-5244171/ jay short still push the 'like' button in linkedin.

1 · Reply

biovaluable Aug. 31 at 3:31 AM

$CNTX is $BCAB season2. bcab is now delisted. bcab tech from china. Chinese scam stock`s sad ending.

0 · Reply

biovaluable Aug. 30 at 8:25 PM

$CNTX $BCAB season2. Be careful.

0 · Reply

biovaluable Aug. 29 at 5:19 AM

$BCAB sec must investigation jay short and his wife.

1 · Reply

LineOfControl Aug. 29 at 12:05 AM

$BCAB did all the execs get their retention payouts before delisting? 🙏

1 · Reply

HjalmarTheGreat Aug. 28 at 9:53 PM

$BCAB I held because an update on clinical trials gov in July 21 caught my attention. On July 21, 2026, BioAtla updated the record for its Phase 3 study of ozuriftamab vedotin (oz-V). What’s interesting is that they didn’t cancel or terminate the study. Instead, the anticipated study start date was pushed back by six months. If BioAtla had completely given up on oz-V, why maintain the Phase 3 trial and simply push the start date out another six months? this does NOT prove that a partnership or acquisition is coming. But it does seem significant that the Phase 3 program was still being maintained as of July 21 rather than being formally abandoned. I don’t think this detail should be overlooked. Maybe there’s nothing more to it. When I saw a 6 month delay I interrupted it as promising. Why update the trial with nothing in the works? Clearly I was off base or will you pull something out after this goes pink? Jay?

0 · Reply

biovaluable Aug. 28 at 9:14 PM

$BCAB bankrupt

0 · Reply

Market Cap	2.89M
Revenue (ttm)	2.00M
Net Income (ttm)	-59.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,980.50%
Debt to Equity Ratio	0.00

Volume	130,200
Avg Vol	84,918
Day's Range	N/A - N/A
Shares Out	1.67M
Stochastic %K	14%
Beta	0.78
Analysts	Hold
Price Target	$10.00